8-K - Co-Diagnostics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Co-Diagnostics reported a full year 2025 net loss of $46.9 million on $0.6 million revenue, driven by an $18.9 million impairment charge, and highlighted regulatory progress for its CoSara joint venture in India.

Key Takeaways

1Revenue fell to $0.6 million in 2025 from $3.9 million in 2024, primarily due to lower grant revenue.

2Operating loss widened to $50.2 million, significantly impacted by an $18.9 million non-cash impairment charge for intangible assets.

3Cash, cash equivalents, and marketable investment securities decreased to $11.9 million as of December 31, 2025, from $29.7 million in the prior year.

4The company raised approximately $10.8 million through two common stock offerings in 2025.

5CoSara Diagnostics received a CDSCO license to manufacture and sell the PCR Pro instrument in India, a key regulatory milestone.

6The company plans an initial FDA 510(k) submission for an upper respiratory test focused on flu A, flu B, and RSV.

Current Report Details

Event Type

Financial Results

Regulation Fd

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 19

Financial Results

7.01

. Regulation FD. Disclosure.** The information set forth under Item 2.02 is incorporated by reference as if fully set forth herein. **Item 9.01 Financial Statem

Regulation Fd

Results of Operations

Full Year 2025

Metric	Value	Basis	Prior Period
Revenue	$0.60		$3.90
Operating Expenses	$50.60		$43.00
Operating Loss	$50.20		$40.10
Net Loss	$46.90		$37.60
Loss Per Share	$35.25		$37.22
Adjusted EBITDA Loss	$28.00	Non-GAAP	$33.50

Exhibits (2)

8-K

99.1

EX-99.1